Navigation Links
Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results
Date:5/7/2008

and general and administrative expenses of $2.7 million compared to $5.5 million and $4.1 million respectively, in the period ending March 31, 2007. Other income for the first quarter of 2008 was $2.5 million, compared to other income of $3.2 million in the first quarter of 2007.

Cash, cash equivalents, and investments as of March 31, 2008 were $9.9 million compared to $13.9 million at March 31, 2007.

The Company anticipates that its existing capital resources are sufficient to enable it to continue operations through August 2008. "Emisphere continues to implement aggressive cost controls to conserve our cash," said Michael V. Novinski, President and Chief Executive Officer. "We believe that by mid-year we will be able to announce partnerships that will enable us to fund the company for some time going forward."

CORPORATE AND PRODUCT DEVELOPMENTS

Emisphere recently announced that preclinical studies using dogs further demonstrate that its proprietary eligen(R) technology enhances the absorption of oral B12. These data confirm in a second animal species Emisphere's earlier reported proof of concept studies conducted in rats.

"These additional studies are an important milestone in our plans to commercialize our eligen(R) technology," said Novinski. "Most importantly, the data is useful to us as we move forward with clinical human trials, which should begin in June 2008. A safe, effective, and better-absorbed oral formulation of vitamin B12 will enable us to move towards commercial success and, ultimately, profits."

There are at least five million people in the United States receiving 40 million B12 injections annually to treat a variety of debilitating medical conditions, and over 600 million tablets of B12 of various strengths are sold in the United States annually. The company believes that 40 million injections suggests a need for an oral B12 preparation that can deliver therapeutic levels of B12, and that the megadoses be
'/>"/>

SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results
2. Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
3. Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008
4. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
5. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
6. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
7. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
8. Emisphere to Host Business Strategy Conference Call on February 7
9. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
10. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
11. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... ... pumps and process equipment, announces the appointment of Dennis Rawle as European Director ... industrial industries. Most recently, he was General Manager and Technical Sales Manager for ...
(Date:8/4/2015)... , August 4, 2015 ... Allied Market Research, titled, "World Cardiac Biomarker - ... biomarker market would generate the revenue of $2,085.9 ... from 2015 to 2020. Cardiac Troponins (T, I) ... forecast period due to high sensitivity and specificity. ...
(Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., a ... non-narcotic, nasally delivered, analgesic drug products, announced today that ... the position of chief medical officer. Dr. Kori brings ... much of which has been focused in the neuroscience ... add Dr. Kori to our clinical team given his ...
(Date:8/4/2015)... ... August 04, 2015 , ... RPS Diagnostics ... – today announced that Robert A. Gregg, PhD, has joined RPS as Senior ... years of relevant experience and remarkable achievements in the medical device and diagnostics ...
Breaking Biology Technology:Dennis Rawle Joins Graphite Metallizing Corporation 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3
... PROVIDENCE, N.J., June 8, 2011 ... eClinical technology, announced today it will preview its forthcoming ... Information Association (DIA) Annual Meeting in Chicago, IL. Guided ... simplify and streamline the startup of electronic trials. It ...
... Telik, Inc. (Nasdaq: TELK ) today announced the ... Telintra in patients with Revlimid refractory or resistant, deletion 5q ... multicenter trial intended to enroll up to 117 evaluable patients. ... patients are transfusion dependent with Low to Intermediate-1 Risk MDS. ...
... Infrared Systems International (OTCBB: IFRS) is pleased to announce that ... its NatuRx™ HIV/AIDS treatment and will push forward with clinical ... a pilot study with two HIV/AIDS patients this week which ... reported AIDS victims on June 5th, 1981. "The ...
Cached Biology Technology:Cmed Technology to Preview New Innovations to Speed and Streamline Electronic Trials at DIA Conference 2Cmed Technology to Preview New Innovations to Speed and Streamline Electronic Trials at DIA Conference 3Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome 2Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome 3Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
(Date:7/31/2015)... The 10 th International Conference on Genomics (ICG-10, ... in Shenzhen , China ... anniversary this year. Since its inauguration in 2006, ICG ... in the ,omics, fields, and is one of the most ... focuses on recent breakthroughs and advances in ,omics, research that ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... Society for Prevention Research (SPR) will hold its annual ... New Jersey Avenue, NW, Washington, D.C., 20001. The ... Reporters can reach authors by registering (free) for the ... 703-615-2466 to schedule media interviews anytime during the meeting. ...
... increase in Hawaii,s mountains, deadly non-native bird diseases ... most of the last disease-free refuges for honeycreepers ... A just-published U.S. Geological Survey (USGS) ... invasion" by examining the present altitudinal range of ...
... disordered may in fact have an unexpected biological role ... study published by researchers at Fox Chase Cancer Center in ... Press). The researchers published the first comprehensive structural ... of bringing together molecular signals between the outer membrane of ...
Cached Biology News:Society for Prevention Research Meeting in Washington, D.C., May 27-29, 2009 2Society for Prevention Research Meeting in Washington, D.C., May 27-29, 2009 3Jeepers creepers: Climate change threatens endangered honeycreepers 2Jeepers creepers: Climate change threatens endangered honeycreepers 3'Disordered' amino acids may really be there to provide wiggle room for signaling protein 2'Disordered' amino acids may really be there to provide wiggle room for signaling protein 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: